Denali Therapeutics (DNLI) to Release Earnings on Thursday

Denali Therapeutics (NASDAQ:DNLI) is expected to post its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.75) per share and revenue of $2.8570 million for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Denali Therapeutics Stock Up 3.3%

DNLI opened at $20.86 on Tuesday. The firm has a market cap of $3.06 billion, a P/E ratio of -7.17 and a beta of 1.02. The business’s fifty day simple moving average is $18.72 and its 200 day simple moving average is $16.91. Denali Therapeutics has a 52 week low of $10.57 and a 52 week high of $23.77. The company has a quick ratio of 9.79, a current ratio of 9.79 and a debt-to-equity ratio of 0.01.

Insider Activity

In other news, insider Alexander O. Schuth sold 17,218 shares of the firm’s stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. This trade represents a 5.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the transaction, the chief executive officer owned 296,833 shares in the company, valued at $4,897,744.50. The trade was a 10.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNLI. Headlands Technologies LLC purchased a new stake in Denali Therapeutics during the 2nd quarter worth $26,000. Johnson Financial Group Inc. purchased a new stake in shares of Denali Therapeutics during the third quarter worth about $29,000. State of Wyoming acquired a new position in shares of Denali Therapeutics in the second quarter worth about $29,000. Aster Capital Management DIFC Ltd purchased a new position in Denali Therapeutics in the fourth quarter valued at about $57,000. Finally, Quarry LP purchased a new position in Denali Therapeutics in the third quarter valued at about $64,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Stifel Nicolaus set a $37.00 target price on shares of Denali Therapeutics in a research note on Monday, November 17th. Wedbush cut their price target on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a report on Thursday, December 11th. BTIG Research restated a “buy” rating and set a $32.00 price objective on shares of Denali Therapeutics in a report on Friday, February 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.27.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.